Business

Avicanna announces the award of two Canadian government NSERC grants: 1) Cannabinoid-based pharmaceutical formulations for the treatment of COVID-19 in collaboration with the University of Toronto; and, 2) Evaluation of cannabinoids for reversing cannabis-based toxicosis in collaboration with the University of Guelph

Avicanna announces the award of two Canadian government NSERC grants: 1) Cannabinoid-based...

articleAvicanna IncJuly 24, 20204/company/avicanna-inc/news/avicanna-announces-the-award-of-two-canadian-government-nserc-grants-1-cannabinoid-based-pharmaceutical-formulations-for-the-treatment-of-covid-19-in-collaboration-with-the-university-of-toronto-and-2-evaluation-of-cannabinoids-for-reversing-cannabis-based-toxicosis-in-collaboration-with-the-university-of-guelph
Avicanna announces the award of two Canadian government NSERC grants: 1) Cannabinoid-based pharmaceutical formulations for the treatment of COVID-19 in collaboration with the University of Toronto; and, 2) Evaluation of cannabinoids for reversing cannabis-based toxicosis in collaboration with the University of Guelph

About this update from Avicanna Inc

[{"type":"text","content":"\n\n\n\nAvicanna announces the award of two Canadian government NSERC grants: 1) Cannabinoid-based pharmaceutical formulations for the treatment of COVID-19 in collaboration with the University of Toronto; and, 2) Evaluation of cannabinoids for reversing cannabis-based toxicosis in collaboration with the University of Guelph\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO, July 24, 2020\n\n\n\nIn addition to a recent MITACS award, Dr. Christine Allen, a Professor at the University of Toronto, was awarded an NSERC Alliance grant for development of cannabinoid-based pharmaceutical formulations for the treatment of COVID-19 induced lung inflammation\nAvicanna further expands its existing neurobiological research collaboration with Dr. Jibran Khokhar, a Professor at the University of Guelph, with a 2-year NSERC Alliance grant to investigate the neural basis of cannabis-induced toxicosis \nThe two NSERC grants leverage the proven track record of Avicanna, the University of Toronto and the University of Guelph in the research and clinical development of cannabinoid-based medicines\n/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/\n TORONTO, July 24, 2020 /CNW/ - Avicanna Inc. (\"Avicanna\" or the \"Company\") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that the Company's research collaborators have received two independent peer-reviewed grants from the Natural Sciences and Engineering Research Council of Canada (\"NSERC\"). The NSERC Alliance grants will be used to expand the investigators' collaborative research with Avicanna.\n\n \n \n \n \n \n \n\n \nFor the past three years, Dr. Christine Allen's research group (CARG) in the Leslie Dan Faculty of Pharmacy at the University of Toronto has supported the develop...

More updates from Avicanna Inc